Similarly, the gene expression profiling of purified CD4+ T-cells from primary tumors, axillary LNs, and peripheral blood of BC patients suggested that a Th1 signature including 12 genes, e.g., chemokine (C-X-C motif) ligand 9 (CXCL9) and IFN-γ, predicts better survival in the human epidermal growth factor receptor 2 (HER2+) BC subtype [19]. The gene discussed is ERBB2; the disease is breast cancer.